Literature DB >> 14253282

TREATMENT OF ACUTE LEUKEMIA WITH METHYLGLYOXAL-BIS-GUANYLHYDRAZONE (METHYL GAG).

R H LEVIN, E HENDERSON, M KARON, E J FREIREICH.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS; CLINICAL RESEARCH; DRUG THERAPY; LEUKEMIA; MERCAPTOPURINE; TOXICOLOGIC REPORT

Mesh:

Substances:

Year:  1965        PMID: 14253282     DOI: 10.1002/cpt19656131

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  7 in total

1.  [Clinico-pharmacologic, cytochemical and Feulgen photometric studies in adult undifferentiated cell leukemias under combination chemotherapy with vincristine, daunorubicine and prednisone].

Authors:  P Obrecht; H Merker; H H Hennekeuser; G Meuret; M Westerhausen; A Simon
Journal:  Klin Wochenschr       Date:  1970-11-01

2.  Acute leukaemia--the current therapeutic position.

Authors:  R B Scott
Journal:  Proc R Soc Med       Date:  1968-05

3.  Leukemia in children.

Authors: 
Journal:  Calif Med       Date:  1971-04

4.  Phase II evaluation of MGBG in non-small cell carcinoma of the lung. A Southwest Oncology Group study.

Authors:  R B Vance; W A Knight; T T Chen; J J Costanzi; A F LoBuglio
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

5.  Pharmacokinetic study of methyl glyoxal-bis-guanylhydrazone (methyl-GAG).

Authors:  M Slavik; T Clouse; A Wood; O Blanc; R C Eschbach
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

6.  Disposition of methylglyoxal bis(guanylhydrazone) (MGBG, NSC-32946) in man.

Authors:  D J Stewart; M G Rosenblum; M Luna; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG).

Authors:  J A Gastaut; G Tell; P J Schechter; D Maraninchi; B Mascret; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.